SciSparc Ltd., a biotechnology company, has submitted Post-Effective Amendment No. 2 to its Registration Statement on Form F-1 to the U.S. Securities and Exchange Commission (SEC) on June 17, 2024. This submission is in response to the SEC's comment letter dated May 16, 2024, regarding the company's initial Post-Effective Amendment No. 1 filed on May 2, 2024. SciSparc has addressed the SEC's comments by revising its prospectus to clarify whether the combined entity, following its merger with AutoMax, will continue the business of SciSparc, AutoMax, or both. Additionally, the company has updated the 'Use of Proceeds' section to specify how the proceeds from the SEPA will be utilized, whether for SciSparc's or AutoMax's operations. SciSparc has also provided a comprehensive discussion of AutoMax's business operations as requested by the SEC. The company acknowledges its responsibility for the accuracy and adequacy of its disclosures.

SciSparc Ltd., a biotechnology company, has submitted Post-Effective Amendment No. 2 to its Registration Statement on Form F-1 to the U.S. Securities and Exchange Commission (SEC) on June 17, 2024. This submission is in response to the SEC's comment letter dated May 16, 2024, regarding the company's initial Post-Effective Amendment No. 1 filed on May 2, 2024. SciSparc has addressed the SEC's comments by revising its prospectus to clarify whether the combined entity, following its merger with AutoMax, will continue the business of SciSparc, AutoMax, or both. Additionally, the company has updated the 'Use of Proceeds' section to specify how the proceeds from the SEPA will be utilized, whether for SciSparc's or AutoMax's operations. SciSparc has also provided a comprehensive discussion of AutoMax's business operations as requested by the SEC. The company acknowledges its responsibility for the accuracy and adequacy of its disclosures.